*Division of Gynecologic Oncology, The University of Alabama at Birmingham, Birmingham, AL

†Mathematica, Washington, DC

‡Seagen Inc., Bothell, WA

§Manatt Health Strategies, New York, NY

This research was funded by Seagen Inc. Seagen conceptualized the study approach, methodology, and contributed to manuscript writing and review, but was not involved in data acquisition, manipulation, or analysis.

C.A.L. has received consulting fees from Seagen for service on Scientific Advisory Boards; cervical cancer research funding from Agenus, Rubius Therapeutics, and Seagen; and funding from the NCI UG1 CA23330 and P50 CA098252. J.T. and Y.J.Z. are employees and stock owners of Seagen Inc. A.F. and N.P. are current employees and J.N. is a former employee of Manatt Health Strategies, which received funding from Seagen Inc. to conduct the study described here. Manatt Health Strategies has also previously received consulting fees from other pharmaceutical companies that they are not permitted to publicly disclose.

Correspondence: Charles A. Leath III, MD, MSPH, 1700 6th Avenue South, WIC 10250 Birmingham, Alabama 35233. E-mail: [email protected].

Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal’s website, www.amjclinicaloncology.com.